Loading...
Market
How many Shield™ tests will Guardant Health sell in the first year after FDA approval?
2
Resolution / Starting Odds
Less than 100,000 • 25%
100,000 to 500,000 • 25%
500,000 to 1,000,000 • 25%
More than 1,000,000 • 25%
Sales reports from Guardant Health
Story
FDA Approves Guardant Health's Shield™ Colorectal Cancer Blood Test on Monday
Jul 29, 2024, 11:00 AM
The U.S. Food and Drug Administration (FDA) has approved Guardant Health's Shield™ blood test as a primary screening option for colorectal cancer. This approval on Monday not only facilitates Medicare reimbursement but also marks a significant advancement in colorectal cancer screening. Guardant Health's blood-based cancer test aims to detect cancer that begins in the colon or rectum, providing a non-invasive alternative to traditional screening methods.
View original story
Similar markets
Below $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
Above $300 million • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Guardant Reveal • 25%
Guardant360 • 25%
GuardantOMNI • 25%
None • 25%
Positive results for Shield • 25%
Positive results for Reveal • 25%
Positive results for Guardant360 • 25%
No positive results • 25%
Yes • 50%
No • 50%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Less than 10,000 units • 25%
10,000 to 50,000 units • 25%
50,000 to 100,000 units • 25%
More than 100,000 units • 25%
Yes • 50%
No • 50%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $200 million • 25%
More than $200 million • 25%